title: Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
authors.affiliation: Dipartimento di Scienze Oftalmologiche, Università Federico II, Naples, Italy. raifor@hotmail.com
authors.forename: R
authors.initials: R
authors.lastname: Forte
authors.forename: G L
authors.initials: GL
authors.lastname: Cennamo
authors.forename: M
authors.initials: M
authors.lastname: Finelli
authors.forename: E
authors.initials: E
authors.lastname: Farese
authors.forename: G
authors.initials: G
authors.lastname: D'Amico
authors.forename: G
authors.initials: G
authors.lastname: Nicoletti
authors.forename: G
authors.initials: G
authors.lastname: de Crecchio
authors.forename: G
authors.initials: G
authors.lastname: Cennamo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D008269:Macular Edema / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014221:Triamcinolone / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab